The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Inlyta axitinib | Pfizer Europe MA EEIG | Carcinoma, Renal Cell | 🇪🇺 EU 2012-09-03 | Order → |
| NovoThirteen catridecacog | Novo Nordisk A/S | Blood Coagulation Disorders, Inherited | 🇪🇺 EU 2012-09-03 | Order → |
| Revestive teduglutide Additional monitoring | Takeda Pharmaceuticals International AG Ireland | Malabsorption Syndromes | 🇪🇺 EU 2012-08-30 | Order → |
| Cuprymina copper (64Cu) chloride | A.C.O.M. - Advanced Center Oncology | Radionuclide Imaging | 🇪🇺 EU 2012-08-23 | Order → |
| Jakavi ruxolitinib | Novartis Europharm Limited | Myeloproliferative Disorders; Polycythemia Vera; Graft vs Host Disease | 🇪🇺 EU 2012-08-23 | Order → |
| Zoledronic acid Mylan zoledronic acid Generic | Mylan Pharmaceuticals Limited | Fractures, Bone | 🇪🇺 EU 2012-08-23 | Order → |
| Zyclara imiquimod | Viatris Healthcare Limited | Keratosis; Keratosis, Actinic | 🇪🇺 EU 2012-08-23 | Order → |
| Zinforo ceftaroline fosamil | Pfizer Ireland Pharmaceuticals | Community-Acquired Infections; Skin Diseases, Infectious; Pneumonia | 🇪🇺 EU 2012-08-22 | Order → |
| Zoledronic acid Teva zoledronic acid Generic | Teva B.V. | Fractures, Bone; Cancer | 🇪🇺 EU 2012-08-16 | Order → |
| Zoledronic acid Teva Pharma zoledronic acid Generic | Teva B.V. | Osteoporosis; Osteitis Deformans; Osteoporosis, Postmenopausal | 🇪🇺 EU 2012-08-15 | Order → |
| Zoledronic acid medac zoledronic acid Generic | medac Gesellschaft für klinische Spezialpräparate mbH | Fractures, Bone; Cancer | 🇪🇺 EU 2012-08-03 | Order → |
| Fycompa perampanel | Eisai GmbH | Epilepsies, Partial | 🇪🇺 EU 2012-07-23 | Order → |
| Kalydeco ivacaftor Accelerated assessment | Vertex Pharmaceuticals (Ireland) Limited | Cystic Fibrosis | 🇪🇺 EU 2012-07-23 | Order → |
| Bretaris Genuair aclidinium bromide | Azurity Pharmaceuticals Ireland Ltd. | Pulmonary Disease, Chronic Obstructive | 🇪🇺 EU 2012-07-20 | Order → |
| Eklira Genuair aclidinium bromide | Azurity Pharmaceuticals Ireland Ltd. | Pulmonary Disease, Chronic Obstructive | 🇪🇺 EU 2012-07-20 | Order → |
| Jentadueto linagliptin;metformin hydrochloride | Boehringer Ingelheim International GmbH | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2012-07-19 | Order → |
| Rienso ferumoxytol Additional monitoring | Takeda Pharma A/S | Anemia; Kidney Failure, Chronic | 🇪🇺 EU 2012-06-15 | Order → |
| Docetaxel Accord docetaxel Generic | Accord Healthcare S.L.U. | Head and Neck Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Prostatic Neoplasms; Breast Neoplasms | 🇪🇺 EU 2012-05-22 | Order → |
| Docetaxel Kabi docetaxel Generic | Fresenius Kabi Deutschland GmbH | Head and Neck Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Prostatic Neoplasms; Breast Neoplasms | 🇪🇺 EU 2012-05-22 | Order → |
| Pixuvri pixantrone dimaleate | Les Laboratoires Servier | Lymphoma, Non-Hodgkin | 🇪🇺 EU 2012-05-10 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.